[發(fā)明專利]用于制備微小RNA 的方法及其治療性應(yīng)用有效
| 申請?zhí)枺?/td> | 201080046930.0 | 申請日: | 2010-09-10 |
| 公開(公告)號: | CN102573856B | 公開(公告)日: | 2016-10-26 |
| 發(fā)明(設(shè)計)人: | 弗萊明·韋林;斯文·林登堡 | 申請(專利權(quán))人: | 弗萊明·韋林;斯文·林登堡 |
| 主分類號: | A61K31/713 | 分類號: | A61K31/713;A61M1/00 |
| 代理公司: | 中國國際貿(mào)易促進委員會專利商標事務(wù)所 11038 | 代理人: | 羅菊華 |
| 地址: | 丹麥弗*** | 國省代碼: | 丹麥;DK |
| 權(quán)利要求書: | 查看更多 | 說明書: | 查看更多 |
| 摘要: | |||
| 搜索關(guān)鍵詞: | 用于 制備 微小 rna 方法 及其 治療 應(yīng)用 | ||
1.包含治療有效量的一種或多種miRNA分子或其功能性變體的組合物,其中在活化體液或其元素之后,所述體液或其元素中的所述miRNA被上調(diào);用作藥物。
2.根據(jù)權(quán)利要求1的組合物,其中所述miRNA是Let-7家族的成員,或其變體。
3.根據(jù)權(quán)利要求1的組合物,其中所述miRNA選自:hsa-Let-7a,hsa-Let-7b,hsa-Let-7b*,hsa-Let-7c,hsa-Let-7d,hsa-Let-7d*,hsa-Let-7e,hsa-Let-7f,hsa-Let-7f*,hsa-Let-7g,hsa-Let-7g*,hsa-Let-7i,hsa-miR-103,hsa-miR-106A,hsa-miR-106B,hsa-miR-107,hsa-miR-125A,hsa-miR-125B,hsa-miR-126,hsa-miR-128,hsa-miR-130A,hsa-miR-130B,hsa-miR-140-3P,hsa-miR-140-5P,hsa-miR-142-3P,hsa-miR-142-5P,hsa-miR-143,hsa-miR-144,hsa-miR-146A,hsa-miR-148A,hsa-miR-148B,hsa-miR-150,hsa-miR-151-3P,hsa-miR-151-5P,hsa-miR-152,hsa-miR-15A,hsa-miR-15B,hsa-miR-16,hsa-miR-15B*,hsa-miR-17,hsa-miR-181A,hsa-miR-185,hsa-miR-186,hsa-miR-18A,hsa-miR-18A*,hsa-miR-18B,hsa-miR-192,hsa-miR-191,hsa-miR-194,hsa-miR-197,hsa-miR-1979,hsa-miR-19A,hsa-miR-19B,hsa-miR-20A,hsa-miR-20B,hsa-miR-21,hsa-miR-205,hsa-miR-210,hsa-miR-215,hsa-miR-22,hsa-miR-22*,hsa-miR-221,hsa-miR-222,hsa-miR-223,hsa-miR-223*,hsa-miR-23A,hsa-miR-23B,hsa-miR-24,hsa-miR-25,hsa-miR-26A,hsa-miR-26B,hsa-miR-27A,hsa-miR-27B,hsa-miR-28-5P,hsa-miR-29A,hsa-miR-29B,hsa-miR-29C,hsa-miR-30A,hsa-miR-301A,hsa-miR-30B,hsa-miR-30C,hsa-miR-30D,hsa-miR-30E,hsa-miR-320A,hsa-miR-320B,hsa-miR-324-3P,hsa-miR-326,hsa-miR-328,hsa-miR-338-3P,hsa-miR-342-3P,hsa-miR-339-5P,hsa-miR-33A,hsa-miR-342-3P,hsa-miR-365,hsa-miR-378,hsa-miR-423-3P,hsa-miR-423-5P,hsa-miR-424,hsa-miR-425,hsa-miR-451,hsa-miR-484,hsa-miR-486-5P,hsa-miR-505,hsa-miR-502-3P,hsa-miR-590-5P,hsa-miR-628-3P,hsa-miR-652,hsa-miR-660,hsa-miR-720,hsa-miR-92A,hsa-miR-92B,hsa-miR-93,hsa-miR-93*,hsa-miR-99A,hsa-miR-99B,hsa-miR-103-2*,hsa-miR-106B*,hsa-miR-133A,hsa-miR-133B,hsa-miR-338-3P,hsa-miR-340,hsa-miR-34A,hsa-miR-34B,hsa-miR-376A,hsa-miR-532-3P,hsa-miR-125A-5P,hsa-miR-154,hsa-miR-196B,hsa-miR-1979,hsa-miR-326,hsa-miR-425*,hsa-miR-127-3P,hsa-miR-1537,hsa-miR-183,hsa-miR-29B-2*,hsa-miR-339-3P,hsa-miR-551A,hsa-miR-629,hsa-miR-766,hsa-miR-2110,hsa-miR-361-3P,hsa-miR-501-5P,hsa-miR-940,hsa-miR-1249,hsa-miR-132,hsa-miR-1538,和hsa-miR-149,hsa-miR-125a-5P,hsa-miR-132,hsa-miR-155,hsa-miR-182,hsa-miR-324-5P,hsa-miR-331-3P,hsa-miR-335,hsa-miR-374b和hsa-miR-532-5P,以及它們的變體。
該專利技術(shù)資料僅供研究查看技術(shù)是否侵權(quán)等信息,商用須獲得專利權(quán)人授權(quán)。該專利全部權(quán)利屬于弗萊明·韋林;斯文·林登堡,未經(jīng)弗萊明·韋林;斯文·林登堡許可,擅自商用是侵權(quán)行為。如果您想購買此專利、獲得商業(yè)授權(quán)和技術(shù)合作,請聯(lián)系【客服】
本文鏈接:http://www.szxzyx.cn/pat/books/201080046930.0/1.html,轉(zhuǎn)載請聲明來源鉆瓜專利網(wǎng)。
- 上一篇:眼鏡蛇神經(jīng)毒素的口服制劑組成與方法
- 下一篇:改進的制劑





